Commentary

Video

Dr Besse on Results From the CARMEN-LC03 Trial in Nonsquamous NSCLC

Author(s):

Benjamin Besse, MD

Fact checked by:

Kyle Doherty
Conference|IASLC World Conference on Lung Cancer

Benjamin Besse, MD, PhD, discusses findings from the phase 3 CARMEN-LC03 trial.

Benjamin Besse, MD, PhD, director, clinical research, and medical oncologist at Institute Gustave Roussy, discusses findings from the phase 3 CARMEN-LC03 trial (NCT04154956), which is examining tusamitamab ravtansine in patients with advanced nonsquamous non–small cell lung cancer (NSCLC).

Related Videos
Marina Chiara Garassino, MD
Nicolas Girard, MD
Benjamin Besse, MD, PhD, director, clinical research, Gustave Roussy Institute; professor, medical oncology, Paris-Saclay University
Nicolas Girard, MD
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Shirish M. Gadgeel, MD
Jacob Sands, MD
Related Content
Eric Kumar Singhi, MD, of MD Anderson Cancer Center
October 9th 2024

Exploring Facets of Both the SCLC and NSCLC Therapeutic Landscapes

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

John V. Heymach, MD, PhD
October 9th 2024

ODAC Weighs In on the Future of Perioperative Trial Designs in Resectable NSCLC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

John Michael Bryant, MD
October 8th 2024

Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer

Isabel Preeshagul, DO, MBS, of Memorial Sloan Kettering Cancer Center
October 7th 2024

Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC